| Leonard V Trapani, MD | |
|
301 University Blvd, Galveston, TX 77555-5302 | |
| (409) 772-1221 | |
| (409) 772-1224 |
| Full Name | Leonard V Trapani |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 34 Years |
| Location | 301 University Blvd, Galveston, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083709364 | NPI | - | NPPES |
| 43117301 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | L5590 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Texas Medical Branch Galveston | Galveston, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Texas Medical Branch Faculty Group Practice | 3375456734 | 875 |
News Archive
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
The University of Mississippi Medical Center will partner with the renowned Mayo Clinic on a series of initiatives intended to convert laboratory discoveries into new therapies and train a new generation of medical scientists.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.
For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.
In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR™1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.
› Verified 6 days ago
| Entity Name | Utmb Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241146 PECOS PAC ID: 3375456734 Enrollment ID: O20031112000438 |
News Archive
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
The University of Mississippi Medical Center will partner with the renowned Mayo Clinic on a series of initiatives intended to convert laboratory discoveries into new therapies and train a new generation of medical scientists.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.
For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.
In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR™1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Leonard V Trapani, MD Po Box 4439, Houston, TX 77210-4439 Ph: (713) 792-2991 | Leonard V Trapani, MD 301 University Blvd, Galveston, TX 77555-5302 Ph: (409) 772-1221 |
News Archive
Long-term use of antiepileptic drugs is a significant risk factor for vitamin D deficiency in children with epilepsy.
The University of Mississippi Medical Center will partner with the renowned Mayo Clinic on a series of initiatives intended to convert laboratory discoveries into new therapies and train a new generation of medical scientists.
Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.
For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.
In a landmark paper, researchers at Stanford University have described a new way to derive human induced pluripotent stem cells (iPSCs) without the use of contaminating mouse feeder cells. Using adipose cells as the starting cell population and mTeSR™1, a defined medium that allows the expansion of human embryonic and induced pluripotent stem cells without the use of feeders, the researchers were able to fully reprogram the cells to the pluripotent state.
› Verified 6 days ago
Sommer Kirsch Causey, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-1221 Fax: 409-772-1224 | |
Heather Tisdale, Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-2222 | |
Riley William Baker, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-266-7856 | |
Fernando Alquicira-macedo, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 301 University Blvd # 2-a, Galveston, TX 77555 Phone: 409-772-1221 Fax: 409-772-1224 | |
Craig Davidson Peiris, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: University Of Texas Medical Branch 301 University Blvd, Galveston, TX 77555 Phone: 409-772-1221 | |
Asle Aarsland, M.D. Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-2222 | |
Erin Michelle Vigil, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 301 University Blvd, Galveston, TX 77555 Phone: 409-772-1221 |